Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding trial of Lu AG09222 for migraine prevention after unsuccessful prior preventive treatments
jRCT2031240164Active, not recruiting
- Sponsor
- Lundbeck
- Start
- Apr 2025
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial in migraine comparing Lu AG09222 with Placebo (2 arms). Primary endpoint: Change from baseline in the number of monthly migraine days. Started Apr 2025; status: active, not recruiting.
02
Drugs
lu ag09222
03
Conditions
migraine
Beyond the preview
Go deeper on jRCT2031240164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240164.